Valeant Pharmaceuticals International (VRX) Sets New 1-Year High at $29.40

Shares of Valeant Pharmaceuticals International, Inc. (TSE:VRX) (NYSE:VRX) reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as C$29.40 and last traded at C$27.24, with a volume of 1404754 shares. The stock had previously closed at C$26.20.

Several analysts have issued reports on the company. Royal Bank of Canada restated a “sector perform” rating and set a C$23.00 price objective on shares of Valeant Pharmaceuticals International in a report on Wednesday, November 8th. TD Securities upgraded Valeant Pharmaceuticals International from a “hold” rating to a “buy” rating and set a C$25.50 price objective on the stock in a report on Wednesday, November 8th.

The company has a market capitalization of $10,040.00, a price-to-earnings ratio of 5.90 and a beta of -0.67.

In other Valeant Pharmaceuticals International news, Director Schutter Richard Urbain De bought 10,000 shares of the company’s stock in a transaction dated Friday, November 17th. The shares were bought at an average price of C$14.33 per share, for a total transaction of C$143,300.00.

TRADEMARK VIOLATION NOTICE: “Valeant Pharmaceuticals International (VRX) Sets New 1-Year High at $29.40” was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this news story can be read at https://www.tickerreport.com/banking-finance/3126445/valeant-pharmaceuticals-international-vrx-sets-new-1-year-high-at-29-40.html.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Receive News & Ratings for Valeant Pharmaceuticals International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2018 Ticker Report. Google+.